PCM Encore’s Pfizer PFE Stock Holding History

PCM Encore’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$451K	Buy	18,738 +552	+3%	+$14.4K	0.08%	233
2026 Q1	$511K	Buy	18,186 +3,259	+22%	+$86.8K	0.11%	202
2025 Q4	$372K	Buy	+14,927	New	+$376K	0.08%	252

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PCM Encore's PFE Position: Q2 2026 in Review

PCM Encore increased its Pfizer (PFE) stake by 3% in Q2 2026, buying an estimated $14.4K and bringing the position to 18,738 shares worth $451K. The position accounts for 0.08% of the portfolio, ranked #233.

PCM Encore first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $511K in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

PCM Encore held 18,738 shares of Pfizer worth $451K as of Q2 2026.
PCM Encore bought 552 Pfizer shares in Q2 2026, an estimated $14.4K.
Pfizer made up 0.08% of PCM Encore's portfolio in Q2 2026, its #233 holding.
PCM Encore first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
PCM Encore's Pfizer position peaked at $511K in Q1 2026.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on PCM Encore's 13F filing for Q2 2026, filed 11 Aug 2026.